The effect of Trachyspermum copticum syrup on clinical manifestations of patients with COVID-19

The effect of Trachyspermum copticum-based traditional medicine product on clinical manifestations and Para clinical features in patients with COVID-19: A Randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180610040049N3

Enrollment

Registered

2020-03-29

Start date

2020-04-08

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Corona Virus. Coronavirus infection, unspecified

Interventions

Intervention 1: "Intervention group:" This group consumes the Trachyspermum copticum syrup. The Trachyspermum copticum plant is a member of the Umbrella family. The total extract of this plant is used

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Having informed consent to participate in the study The definitive diagnosis of COVID-19 Failure to attend another clinical trial simultaneously

Exclusion criteria

Exclusion criteria: Patient's willingness to use other therapies Alzheimer's patients

Design outcomes

Primary

Measure	Time frame
Level of CRP in serum. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: Using the ELISA technique.;The rate of lung inflammation. Timepoint: One day before the intervention and one day after the intervention is measured. Method of measurement: CT SCAN.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeied Amirhosein Latifi

Arak University of Medical Sciences

seiedalatifi@yahoo.com+98 86 3417 3601

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026